Karyopharm to Participate at Upcoming Investor Conferences
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced participation in two investor conferences this September.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced participation in two investor conferences this September. The Morgan Stanley 20th Annual Global Healthcare Conference will take place on September 12, 2022, at 12:30 p.m. ET, followed by the Baird 2022 Global Healthcare Conference on September 13, 2022, at 12:50 p.m. ET. Live webcasts and slides will be available on their website for 90 days post-event. Karyopharm specializes in oral cancer treatments, including its lead compound, XPOVIO®.
Details
News Market Reaction – KPTI
The recorded move for KPTI in the trading session of this news was +4.14%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., Sept. 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:
Morgan Stanley 20th Annual Global Healthcare Conference
Format: Fireside chat
Date: Monday, September 12, 2022
Time: 12:30 p.m. ET
Baird 2022 Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, September 13, 2022
Time: 12:50 p.m. ET
A live webcast of the fireside chats, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations, and will be available for replay for 90 days following each fireside chat.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China, Singapore, Canada, Israel, South Korea and Australia. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on Twitter at @Karyopharm and LinkedIn.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-upcoming-investor-conferences-301618616.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.